Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines

Vaccine

Volumn 26, Issue 37, 2008, Pages 4819-4829

  Xu, Rong ^a   Megati, Shakuntala ^a   Roopchand, Vidia ^a   Luckay, Amara ^a   Masood, Amjed ^a   Garcia Hand, Dorys ^a   Rosati, Margherita ^b   Weiner, David B ^c   Felber, Barbara K ^b   Pavlakis, George N ^b   Sidhu, Maninder K ^a   Eldridge, John H ^a   Egan, Michael A ^a  

^a WYETH RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chemokine; Cytokine; HIV; Molecular adjuvant; Plasmid DNA

Indexed keywords

ADJUVANT; CHEMOKINE; CYTOKINE; DNA VACCINE; FLT3 LIGAND; GAG PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; NEF PROTEIN; PLASMID DNA; TRANSACTIVATOR PROTEIN; VIF PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS TITRATION;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HIV-1; INTERLEUKIN-12; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; PLASMIDS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA;

EID: 49549106212     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.06.103     Document Type: Article

References (54)

1. Gurunathan S., Stobie L., Prussin C., Sacks D.L., Glaichenhaus N., Fowell D.J., et al. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J Immunol 165 2 (2000) 915-924
2. Donnelly J.J., and Ulmer J.B. DNA vaccines for viral diseases. Braz J Med Biol Res 32 2 (1999) 215-222
3. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., and Robinson H.L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 90 24 (1993) 11478-11482
4. Robinson H.L., Hunt L.A., and Webster R.G. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 11 9 (1993) 957-960
5. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 5102 (1993) 1745-1749
6. Babiuk L.A., van Drunen Littel-van den H., and Babiuk S.L. Immunization of animals: from DNA to the dinner plate. Vet Immunol Immunopathol 72 1-2 (1999) 189-202
7. Egan M.A., Charini W.A., Kuroda M.J., Schmitz J.E., Racz P., Tenner-Racz K., et al. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. J Virol 74 16 (2000) 7485-7495
8. MacGregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178 1 (1998) 92-100
9. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 5388 (1998) 476-480
10. Lu S., Wang S., and Grimes-Serrano J.M. Current progress of DNA vaccine studies in humans. Expert Rev Vacc 7 2 (2008) 175-191
11. Trimble C., Lin C.T., Hung C.F., Pai S., Juang J., He L., et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 21 25-26 (2003) 4036-4042
12. Herrmann J.E., Chen S.C., Jones D.H., Tinsley-Bown A., Fynan E.F., Greenberg H.B., et al. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology 259 1 (1999) 148-153
13. Chen S.C., Jones D.H., Fynan E.F., Farrar G.H., Clegg J.C., Greenberg H.B., et al. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 72 7 (1998) 5757-5761
14. Sharpe M., Lynch D., Topham S., Major D., Wood J., and Loudon P. Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery. Vaccine 25 34 (2007) 6392-6398
15. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164 9 (2000) 4635-4640
16. Otten G., Schaefer M., Doe B., Liu H., Srivastava I., Megede J.Z., et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22 19 (2004) 2489-2493
17. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.-Y., Roopchand V., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 81 10 (2007) 5257-5269
18. Andre S., Seed B., Eberle J., Schraut W., Bultmann A., and Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72 2 (1998) 1497-1503
19. Schneider R., Campbell M., Nasioulas G., Felber B., and Pavlakis G. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 71 7 (1997) 4892-4903
20. Otten G.R., Schaefer M., Doe B., Liu H., Srivastava I., Megede J., et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol 79 13 (2005) 8189-8200
21. Egan M.A., Chong S.-Y., Megati S., Montefiori D.C., Rose N.F., Sidhu M., et al. Priming with plasmid DNAs expressing IL-12 and SIV Gag protein enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses 7 (2005) 629-643
22. Robinson H.L. Prime boost vaccines power up in people. Nat Med 9 6 (2003) 642-643
23. Egan M.A., and Israel Z.R. The use of cytokines and chemokines as genetic adjuvants for plasmid DNA vaccines. Clin Appl Immunol Rev 2 (2002) 255-287
24. Barouch D.H., Letvin N.L., and Seder R.A. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev 202 (2004) 266-274
25. Moore A.C., Kong W.P., Chakrabarti B.K., and Nabel G.J. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J Virol 76 1 (2002) 243-250
26. Boyer J.D., Robinson T.M., Kutzler M.A., Parkinson R., Calarota S.A., Sidhu M.K., et al. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol 34 5-6 (2005) 262-270
27. Schadeck E.B., Sidhu M., Egan M.A., Chong S.-Y., Piacente P., Masood A., et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 24 21 (2006) 4677-4687
28. Kusakabe K., Xin K.Q., Katoh H., Sumino K., Hagiwara E., Kawamoto S., et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 164 6 (2000) 3102-3111
29. Barouch D.H., Santra S., Tenner-Racz K., Racz P., Kuroda M.J., Schmitz J.E., et al. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 168 2 (2002) 562-568
30. McKay P.F., Barouch D.H., Santra S., Sumida S.M., Jackson S.S., Gorgone D.A., et al. Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur J Immunol 34 4 (2004) 1011-1020
31. Qiu J.-T., Chang T.-C., Lin C.-T., Chen Y.-M., Li F.Q., Soong Y.-K., et al. Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 Gag. Vaccine 25 2 (2007) 253-263
32. Sumida S.M., McKay P.F., Truitt D.M., Kishko M.G., Arthur J.C., Seaman M.S., et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest 114 9 (2004) 1334-1342
33. Nayak B.P., Sailaja G., and Jabbar A.M. Augmenting the immunogenicity of DNA vaccines: role of plasmid-encoded Flt-3 ligand, as a molecular adjuvant in genetic vaccination. Virology 348 2 (2006) 277-288
34. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8(+) T cells. Blood 107 12 (2006) 4781-4789
35. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses. J Exp Med 204 6 (2007) 1405-1416
36. Schwartz S., Campbell M., Nasioulas G., Harrison J., Felber B.K., and Pavlakis G.N. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol 66 12 (1992) 7176-7182
37. Schwartz S., Felber B.K., and Pavlakis G.N. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 66 1 (1992) 150-159
38. Aiken C., Konner J., Landau N.R., Lenburg M.E., and Trono D. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76 5 (1994) 853-864
39. Sadaie M.R., Rappaport J., Benter T., Josephs S.F., Willis R., and Wong-Staal F. Missense mutations in an infectious human immunodeficiency viral genome: functional mapping of tat and identification of the rev splice acceptor. PNAS 85 23 (1988) 9224-9228
40. HIV Immunology and HIV/SIV Vaccine Databases: Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico. LA-UR 04-8162; 2003.
41. Egan M.A., Megati S., Roopchand V., Garcia-Hand D., Luckay A., Chong S.-Y., et al. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. Vaccine 24 21 (2006) 4510-4523
42. Shaw K.J., Rather P.N., Hare R.S., and Miller G.H. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 57 1 (1993) 138-163
43. Sadaie Y., Burtis K.C., and Doi R.H. Purification and characterization of a kanamycin nucleotidyltransferase from plasmid pUB110-carrying cells of Bacillus subtilis. J Bacteriol 141 3 (1980) 1178-1182
44. Cooper C.L., Brady G., Bilia F., Iscove N.N., and Quesenberry P.J. Expression of the Id family helix-loop-helix regulators during growth and development in the hematopoietic system. Blood 89 9 (1997) 3155-3165
45. Pachuk C.J., Ciccarelli R.B., Samuel M., Bayer M.E., Troutman R.D., Zurawski D.V., et al. Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine. Biochim Biophys Acta 1468 1-2 (2000) 20-30
46. Maraskovsky E., Brasel K., Teepe M., Roux E.R., Lyman S.D., Shortman K., et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 184 5 (1996) 1953-1962
47. Jones T.C. Future uses of granulocyte-macrophage colony-stimulating factor (GM-CSF). Stem Cells 12 Suppl. 1 (1994) 229-239 [discussion 39-40]
48. Disis M.L., Bernhard H., Shiota F.M., Hand S.L., Gralow J.R., Huseby E.S., et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88 1 (1996) 202-210
49. Haddad D., Ramprakash J., Sedegah M., Charoenvit Y., Baumgartner R., Kumar S., et al. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol 165 7 (2000) 3772-3781
50. Lai L., Vodros D., Kozlowski P.A., Montefiori D.C., Wilson R.L., Akerstrom V.L., et al. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 369 1 (2007) 153-167
51. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., and Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68 9 (1994) 6103-6110
52. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 7 (1994) 4650-4655
53. Betts M.R., Brenchley J.M., Price D.A., De Rosa S.C., Douek D.C., Roederer M., et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281 1-2 (2003) 65-78
54. Perfetto S.P., Chattopadhyay P.K., and Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Immunology 4 8 (2004) 648-655